Life sciences
F-Star
Novo AS of Copenhagen has added Euro 3 million ($4.43 million) to a Euro 6 million Series A round of funding for F-Star Biotechnologische Forschungs- und Entwicklungs GmbH of Vienna, an antibody engineering company. Existing investors in the round included Aescap Venture of Amsterdam and Atlas Venture of London. The company has raised a total of Euro 13 million, including a seed round, since 2006. - P.B.
RadPharm
Princeton, N.J. medical imaging specialist RadPharm Inc. raised $10 million in a Series B round led by Siemens Venture Capital to aggressively expand contract research services to pharmaceutical companies that use its independent review and analysis capabilities in cancer drug development. The deal includes previous investors Ampersand Ventures of Wellesley, Mass., Adams Street Partners of Boston and Tang Capital Management, and follows up on an $8 million first round closed in March 2006 that has allowed the Princeton, N.J., company to spin out of its roots in an independent radiology clinic and establish itself as a standalone contract research organization. To date, RadPharm has provided image analysis used by more than 60 sponsors in 250 clinical trials. - Clifford Carlsen
Information technology
Avail Media
Reston, Va., Internet television infrastructure provider Avail Media Inc. landed $8 million in follow-on funding from new investor Valhalla Partners of Vienna, Va., and existing investors to close a $25 million Series B round of financing. The deal comes on top of $17 million the company closed in May from Columbia Capital of Alexandria, Va., Novak Biddle Venture Partners of Bethesda, Md., and Seattle-based Pioneer Ventures, and along with $5 million in debt funding from Silicon Valley Bank and an unnamed strategic partner, brings total funding in the 10-month-old company to $30 million. The funding will allow the company to expand marketing of video-on-demand and other Internet protocol television content and services to telecommunications carriers, and is expected to be sufficient to take the company to profitability in 2009. - C.C.
Industrial
Allylix
Flavor, fragrance and drug chemical developer Allylix Inc. of San Diego has attracted $3.35 million in its first institutional round of venture funding. Participants included Tech Coast Angels of Los Angeles; Life Science Angels of Palo Alto, Calif.; Bluegrass Angels of Lexington, Ky.; Pasadena Angels of Altadena, Calif.; and Tate & Lyle Ventures of London. Allylix expects to launch its first three products in a line of natural and synthetic chemicals which will address the flavor & fragrance, pharmaceutical, nutraceutical and agricultural markets. - P.B.
